Platelet-rich fibrin as a treatment option for osteoradionecrosis: A literature review

J Stomatol Oral Maxillofac Surg. 2022 Jun;123(3):e20-e27. doi: 10.1016/j.jormas.2021.06.005. Epub 2021 Jun 23.


The aim of this review is to establish the usefulness and effectiveness of using platelet-rich fibrin (PRF) in the treatment of osteoradionecrosis (ORN) lesions. A review of the literature was performed using keywords through the PubMed-Medline and Cochrane Library search engine. Inclusion criteria were: (1) original publication in either the French or the English language, (2) studies conducted in humans, (3) presence of ORN lesions following head and neck radiotherapy (RT), (4) use of PRF or derivates in the treatment of ORN lesions, (5) clinical variables and outcomes mentioned in the study. Overall, four case reports were retained. Two publications were removed from the initial seven results after application of the inclusion criteria. A recent randomised clinical trial was not considered since the group analysed the effectiveness of leukocyte-enriched Plasmas-Rich-Fibrin (LPRF) in preventing ORN, but not in treating it. Therefore, four publications were retained for analysis. Results suggest that using PRF as an adjunct to surgical therapy is beneficial in treating ORN lesions although no controlled studies were found. Therefore, additional controlled clinical studies are warranted to better define the effectiveness and recommendation of this approach.

Keywords: Head and neck cancer; Jaw diseases; Osteoradionecrosis; Platelet-rich fibrin; Radiation therapy; Radiotherapy.

Publication types

  • Review

MeSH terms

  • Head and Neck Neoplasms* / radiotherapy
  • Humans
  • Neck
  • Osteoradionecrosis* / etiology
  • Osteoradionecrosis* / pathology
  • Osteoradionecrosis* / therapy
  • Platelet-Rich Fibrin*